{"url_path":"/sec/jbio/8-k/2026-06-01/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1798749/0001193125-26-249763-index.html","accession_number":"0001193125-26-249763","cik":"0001798749","ticker":"JBIO","issuer_name":"Jade Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1798749/0001193125-26-249763-index.html","primary_entity_key":"0001798749","primary_entity_name":"Jade Biosciences, Inc."},"word_count":202,"has_tables":true,"body_markdown":"Item 7.01.\n\nRegulation FD Disclosure.\n\nOn June 1, 2026, Jade Biosciences, Inc. (“Jade” or the “Company”) will host a conference call and webcast to share interim results from its Phase 1 healthy volunteer trial evaluating JADE101, a novel, investigational anti-A Proliferation-Inducing Ligand (“APRIL”) monoclonal antibody in development for the treatment of immunoglobulin A nephropathy (“IgAN”). The event will begin at 8:00 a.m. Eastern Time and will be available via a live webcast accessible on the “Events and Presentations” page of Jade’s corporate website at www.jadebiosciences.com. During the event, the Company will present the corporate slide presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference.\n\nThe information contained in this Item 7.01, including in Exhibit 99.1 hereto and on Jade’s corporate website, is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}